Elanco Animal Health (ELAN)

• Market cap: $5.97B
• 1 day: 0.17%
• 5 days: 0.50%
• 1 month: 1.68%
• 3 months: -2.50%
• 6 months: -7.29%
• Year to date: 0.25%
• 1 year: -17.03%
• 5 years: -61.74%
• 10 years: -66.44%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Employees: 9,800

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

405% more call options, than puts

Call options by funds: $81.4M | Put options by funds: $16.1M

133% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 7 (+4) [Q3]

31% more repeat investments, than reductions

Existing positions increased: 157 | Existing positions reduced: 120

1% more capital invested

Capital invested by funds: $7.09B [Q2] → $7.17B (+$78.6M) [Q3]

0.69% less ownership

Funds ownership: 99.49% [Q2] → 98.8% (-0.69%) [Q3]

4% less funds holding

Funds holding: 398 [Q2] → 383 (-15) [Q3]

17% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 63

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 16% upside
• Avg. target: $17.50 45% upside
• High target: $20 66% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Stifel Jonathan Block 42% 1-year accuracy 8 / 19 met price target	49% upside $18	Buy Maintained	7 Jan 2025
UBS Andrea Alfonso 0% 1-year accuracy 0 / 1 met price target	49% upside $18	Buy Initiated	9 Dec 2024
Leerink Partners Daniel Clark 50% 1-year accuracy 1 / 2 met price target	16% upside $14	Market Perform Initiated	2 Dec 2024
Barclays Balaji Prasad 49% 1-year accuracy 22 / 45 met price target	66% upside $20	Overweight Maintained	8 Nov 2024